Enhancing Clinical Trial in the Digital Era with AI
The healthcare industry is itself a universe. Yet, it has been quite slow to embrace the power of data to increase outcomes and realize the potential of today’s digital technologies. Now is the time to bring changes to the healthcare industry. What we need now is a powerful catalyst for change in the healthcare system- Intelligent Healthcare.
Smart healthcare service implies making machines central to our healthcare condition by systematizing routine procedures and methods so clinicians can use deep learning to recognize critically sick patients and give actionable insights for care. Thus, clinicians will be able to more productively and viably analyze and treat patients. Smart healthcare service also implies computerizing billing, documentation, and administrative procedures so that clinicians can concentrate on addressing each patient’s needs.
Parallel to these developments is the digital revolution, which is rapidly changing what is conceivable in health services. Medical artificial intelligence (AI) is predicted to increase in predominance in clinical trials this year due to the capacity of computers and machines to perform tasks generally requiring human thought. This new capacity should eventually enhance the quality, security, and time-to-market of rising treatments.
AI is a promising innovation that could be connected to many stages of drug discovery and advancement, including target identification, lead streamlining, drug repurposing, patient identification proof, etc. AI can more productively recognize better targets by rapidly seeking a great many references to various sources. Treatment of perpetual and deadly diseases, like Alzheimer’s Disease, could benefit from such new advancements.
AI has the capacity to comprehend natural language and clinical notes alongside structured information like numbers and dates. It also has the capacity to build theories in view of the evidence. Due to these abilities, AI is being considered for AI-Powered Clinical Trials, of which the healthcare and pharmaceutical industries would be the greatest beneficiaries. Artificial intelligence holds the prominent potential to change clinical research and lower costs related to disease management, successful aging, and the discovery and improvement of new medicines. AI has a promising future. Pharmaceutical companies need to assess their needs to create a pathway to adopting advanced clinical trials. Certain activities can be embraced horizontally over various medical areas, while others might be particular to specific areas.
It is necessary and important to conceive of the future with optimistic yet practical targets and venture into digital clinical trials. Prompt action by drug development organizations can result in competitive differentiation in the creation of drugs through clinical trials.
Read the White Paper – ENHANCING CLINICAL TRIAL in the DIGITAL ERA with AI
Scalable Health specializes in providing next-generation healthcare data, analytics and digital transformation solutions enabling healthcare organizations to optimize healthcare.
We provide and support healthcare technology solutions that employ next-generation technologies such as Big Data, Social, Mobile, and Cloud to deliver cost-effective real-time platforms and products enabling healthcare organizations to improve health care significantly, to manage patients and diseases efficiently with personalized care, reduce fraud and waste, accelerate drug development and achieve operational excellence.
Our focus on technology innovation and collaboration with world’s leading technology companies helps us stay ahead of the curve. With extensive capabilities in healthcare technology, world-class service quality and a global resource base, Scalable Health understands industry-specific challenges. Our value lies in our ability to link the best technology solution to complex business challenges in the most cost-effective and innovative way. Headquartered in New Jersey, we are a Minority Certified company by the National Minority Supplier Development Council and State of New Jersey, with operations in the USA, Europe, and Asia.